Mechanism of Action of UDCA in Cholelithiasis Treatment
UDCA dissolves cholesterol gallstones by suppressing hepatic cholesterol synthesis and secretion, inhibiting intestinal cholesterol absorption, and converting bile from cholesterol-precipitating to cholesterol-solubilizing through unique dispersion of cholesterol as liquid crystals in aqueous media. 1
Primary Mechanisms
1. Cholesterol Metabolism Alteration
UDCA fundamentally changes how the body handles cholesterol at multiple sites:
- Suppresses hepatic cholesterol synthesis and secretion - This reduces the amount of cholesterol available for gallstone formation 1
- Inhibits intestinal cholesterol absorption - Prevents dietary cholesterol from entering the bile acid pool 1
- Does NOT significantly affect endogenous bile acid synthesis or phospholipid secretion - The drug is selective in its cholesterol-targeting effects 1
Research confirms UDCA may specifically inhibit cholesterol synthesis at the squalene synthase or 4α-demethylase steps, with biliary lanosterol and lathosterol levels decreasing by 43% and 34% respectively 2.
2. Cholesterol Solubilization
The most clinically relevant mechanism involves changing bile composition:
Enriches bile acid pool with UDCA - Reaches steady-state at approximately 60% of total bile acid pool within 3 weeks of dosing 1
Solubilizes cholesterol through dual mechanisms:
- Traditional micellar solubilization
- Unique dispersion as liquid crystals - This is an apparently unique mechanism specific to UDCA that allows cholesterol solubilization even in aqueous media 1
Increases cholesterol saturation threshold - The overall effect transforms bile from cholesterol-precipitating to cholesterol-solubilizing 1
3. Enterohepatic Circulation
UDCA works primarily in the liver, bile, and gut lumen:
- 90% absorbed in small bowel after oral administration 1
- Large first-pass hepatic extraction - Conjugated with glycine or taurine, then secreted into bile 1
- Concentrated in gallbladder and expelled into duodenum with meals 1
- Minimal systemic circulation - Very small amounts reach urine; therapeutic action is local 1
Clinical Efficacy for Gallstone Dissolution
At the optimal dose of 8-10 mg/kg/day, complete stone dissolution occurs in approximately 30% of unselected patients with uncalcified gallstones <20 mm treated for up to 2 years 1.
Factors Predicting Success:
Stone characteristics matter most:
Patient factors do NOT predict success: Age, sex, weight, obesity degree, and serum cholesterol are unrelated to dissolution rates 1
Important Caveats:
- Gallbladder nonvisualization developing during treatment predicts failure - Therapy should be discontinued if this occurs 1
- Partial dissolution at 6 months indicates >70% chance of eventual complete dissolution 1
- Stone recurrence occurs in up to 50% of patients within 5 years after complete dissolution 1
Additional Mechanisms (Secondary Benefits)
Recent research suggests UDCA may also:
- Improve gastrointestinal motility - Reduces gastric emptying time and intestinal transit time in gallstone patients 3
- Enhance gallbladder contractility - Despite increasing fasting gallbladder volume, in vitro contractility actually improves, possibly related to reduced biliary cholesterol saturation 4
Practical Considerations
The mechanism requires time to work - after UDCA is stopped, bile acid concentration falls exponentially to 5-10% of steady-state within 1 week 1. This explains why continuous therapy is necessary for stone dissolution and why recurrence is common after discontinuation.
The drug's therapeutic actions occur specifically in the liver, bile, and gut lumen - not systemically - which explains its excellent safety profile and why systemic side effects are minimal 1.